Jeet Mukherjee
Stock Analyst at BTIG
(4.37)
# 361
Out of 5,124 analysts
18
Total ratings
66.67%
Success rate
19.07%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeet Mukherjee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FHTX Foghorn Therapeutics | Initiates: Buy | $11 | $4.98 | +120.88% | 1 | Dec 18, 2025 | |
| PVLA Palvella Therapeutics | Maintains: Buy | $167 → $192 | $88.44 | +117.10% | 2 | Dec 15, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Buy | $27 → $30 | $17.49 | +71.53% | 4 | Dec 9, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Buy | $75 → $138 | $72.41 | +90.58% | 3 | Dec 9, 2025 | |
| AARD Aardvark Therapeutics | Initiates: Buy | $26 | $13.28 | +95.78% | 1 | Nov 7, 2025 | |
| ARVN Arvinas | Maintains: Buy | $10 → $14 | $11.17 | +25.34% | 2 | Oct 30, 2025 | |
| CATX Perspective Therapeutics | Reiterates: Buy | $14 | $2.73 | +412.82% | 2 | Oct 13, 2025 | |
| MNPR Monopar Therapeutics | Maintains: Buy | $87 → $104 | $61.73 | +68.48% | 3 | Sep 25, 2025 |
Foghorn Therapeutics
Dec 18, 2025
Initiates: Buy
Price Target: $11
Current: $4.98
Upside: +120.88%
Palvella Therapeutics
Dec 15, 2025
Maintains: Buy
Price Target: $167 → $192
Current: $88.44
Upside: +117.10%
Nurix Therapeutics
Dec 9, 2025
Maintains: Buy
Price Target: $27 → $30
Current: $17.49
Upside: +71.53%
Kymera Therapeutics
Dec 9, 2025
Maintains: Buy
Price Target: $75 → $138
Current: $72.41
Upside: +90.58%
Aardvark Therapeutics
Nov 7, 2025
Initiates: Buy
Price Target: $26
Current: $13.28
Upside: +95.78%
Arvinas
Oct 30, 2025
Maintains: Buy
Price Target: $10 → $14
Current: $11.17
Upside: +25.34%
Perspective Therapeutics
Oct 13, 2025
Reiterates: Buy
Price Target: $14
Current: $2.73
Upside: +412.82%
Monopar Therapeutics
Sep 25, 2025
Maintains: Buy
Price Target: $87 → $104
Current: $61.73
Upside: +68.48%